Researchers have identified UCHL1 (Ubiquitin C-terminal Hydrolase L1) as a critical protein that accelerates the growth of gastric cancer cells. This discovery, led by Professor Kim Hee-seong from Hanlim University Sacred Heart Hospital’s Biomedical Research Institute, highlights UCHL1’s role in tumor progression through the ubiquitin-proteasome system (UPS).
Gastric Cancer: A Global Health Challenge
Gastric cancer ranks as the fourth most common cancer worldwide, claiming numerous lives annually. Despite advances in treatments like surgery, chemotherapy, and radiation, its partial breakdown remains a significant hurdle, emphasizing the need for targeted therapies.
Breakthrough Analysis of Tumor Tissues
The research team compared protein levels in tumor tissues from 48 gastric cancer patients against adjacent healthy tissues. Results showed UCHL1 levels in cancer tissues exceeded those in normal tissues by over 70%. Elevated UCHL1 correlated directly with larger tumor sizes, confirming its direct involvement in cancer advancement.
Mechanism: Targeting UPS and CIP2A
UCHL1 influences cancer cell survival and proliferation via the UPS, which regulates protein degradation. Further experiments revealed UCHL1 stabilizes CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A), preventing its breakdown. CIP2A activates c-Myc signaling, a key driver of cancer cell growth.
Inhibition Shows Promise
Applying the UCHL1 inhibitor LDN-57444 to gastric cancer cells halted their division, arresting growth in the G1 phase. This outcome supports UCHL1’s potential as a therapeutic target, paving the way for new drugs and precise therapies.
Expert Insights
Professor Kim Hee-seong stated, “This study confirms UCHL1 acts as a tumor promoter in gastric cancer, accurately identifying it as a key driver of cancer growth.” He added, “Developing therapies targeting UCHL1, along with predictive biomarkers, holds great promise for future research.”
The findings appear in the latest issue of Pharmaceuticals under the title “UCHL1 Promotes Gastric Cancer Progression by Regulating CIP2A Degradation.”
